Meridian Bioscience Announces FDA Submission for New Curian® Campy Assay
Curian® Campy, for use with the Curian® Analyzer, is a rapid, qualitative fluorescent immunoassay for the detection of Campylobacter spp. (C. jejuni / C. coli / C. upsaliensis / C. lari) in human stool. The stool sample may be either unpreserved or preserved in Cary-Blair-based transport media.
The Curian® solution provides objective, rapid test results and helps to eliminate subjectivity by reducing user variability related to interpreting and reporting visually-based test results. With a simple workflow and clean, comfortable sample handling, Curian® provides healthcare systems a platform to standardize testing from the industry’s leading experts in stool handling and testing.
For more information on the Curian® platform, please visit https://www.meridianbioscience.com/platform/immunoassay/curian/.
Meridian is a fully integrated life science company that develops, manufactures, markets and distributes a broad range of innovative diagnostic products. We are dedicated to developing and delivering better solutions that give answers with speed, accuracy and simplicity that are redefining the possibilities of life from discovery to diagnosis. Through discovery and development, we provide critical life science raw materials used in immunological and molecular tests for human, animal, plant, and environmental applications. Through diagnosis, we provide diagnostic solutions in areas including gastrointestinal and upper respiratory infections and blood lead level testing. We build relationships and provide solutions to hospitals, reference laboratories, research centers, veterinary testing centers, physician offices, diagnostics manufacturers, and biotech companies in more than 70 countries around the world.
Meridian’s shares are traded on the NASDAQ Global Select Market, symbol
Vice President – Investor Relations
Phone: +1 513.271.3700
Source: Meridian Bioscience Inc.